SOUTH CAROLINA: AIDS Drugs Take Financial Toll on Patients

Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.

SOUTH CAROLINA: AIDS Drugs Take Financial Toll on Patients

The State (Columbia) (12.01.05) - Tuesday, December 06, 2005
Czerne M. Reid

While new medicines and improved services help people infected with HIV/AIDS live longer, more productive lives, the economic burden is high. "HIV is not just a health issue, it's also an issue of economics," Carmen Julious, executive director of Palmetto AIDS Life Support Services, said of antiretroviral regimens that can cost $24,000 a year.

South Carolina's AIDS Drug Assistance Program (ADAP) serves close to 3,000 low-income residents. It covers all Food and Drug Administration-approved antiretroviral medicines and treatments for opportunistic infections like pneumonia and shingles. It also helps with insurance premiums, co-pays and deductibles.

In the face of increasing demand and budget shortfalls, ADAP officials in Columbia have found ways to keep it running without cutting services. Last year, the program received $14 million in federal funding and $500,000 from the state. Through negotiated drug discounts, generic drugs, and low administrative costs, ADAP officials have stretched program dollars.

South Carolina also got low drug pricing as a public-health provider, and it received a $1.3 million supplemental grant last year, said Melissa Villnow, the state's ADAP director. However, it is not clear if the program will get the grant in coming years.
051206
AD052455

Copyright © 2005 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.